Abstract 4897
Background
A noninvasive cfDNA test to detect early-stage pancreatic ductal adenocarcinoma (PDAC) is highly desirable to reduce PDAC’s high mortality rate. DNA methylation markers are promising to differentiate PDAC tissues from benign pancreas tissues, which may lead to liquid biopsy tests for PDAC early screening.
Methods
We have collected freshly frozen clinical PDAC tissues (N = 46), para-tumour pancreas tissues (N = 30), PDAC plasma samples (N = 120), chronical pancreatitis plasma samples (N = 90), and normal plasma samples (N = 100). Genomic DNA and circulating tumour DNA (ctDNA) samples were isolated and purified. DNA methylation profiles were generated by reduced representation bisulfite sequencing (RRBS). We quantified DNA methylation status of Methylation Haplotype Blocks (MHB) using Methylation Haplotype Load (MHL). Tumour-specific DNA methylation signatures were identified for PDAC by comparing MHL scores between PDAC and para-tumour pancreas tissues, PDAC tissues with normal cell-free circulating DNA (cfDNA), and PDAC ctDNA with normal cfDNA samples.
Results
We identified 350 of MHBs by combining unique MHBs identified in each comparison. Using MHB selected from tissue-vs-tissue comparison to build classifiers, we reiterated training and cross-validating PDAC tissue classification models using SVM method, and achieved the average sensitivity of 86% specificity of 88%, and AUC of 0.91. Other machine learning methods generated similar results. We further compared our markers with previously published DNA methylation markers for PDAC, and found that genes associated with published markers are highly enriched in the genes associated with our markers (p < 1E-20; hypergeometric test), indicating they may co-regulate a same set of genes that are involved in PDAC pathology. We have further developed NGS based panels and algorithms to classify PDAC patients using cell-free DNA (cfDNA) samples based on the identified methylation markers.
Conclusions
Using multiple metrics on MHBs, we identified PDAC-specific DNA methylation markers, some of which are functionally overlapped with previously reported markers. These markers are candidate biomarkers for non-invasive PDAC screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Peking Union Medical College Hospital and Singlera Genomics Inc.
Funding
China Science and Technology Exchange Center.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2840 - Effects of Aerobic and Resistance Exercise on Android:Gynoid Fat Ratio in Breast Cancer Survivors
Presenter: Christina Dieli-Conwright
Session: Poster Display session 2
Resources:
Abstract
869 - Impact of Education for Breast self examination in Rural Indian Women on Early Detection - results of POC study
Presenter: Sneha Parchuri
Session: Poster Display session 2
Resources:
Abstract
1951 - Breast cancer incidence and survival in renal transplant patients: 35-year experience
Presenter: Michalis Kontos
Session: Poster Display session 2
Resources:
Abstract
2017 - The changing landscape of breast cancer incidence after treatment for Hodgkin’s disease
Presenter: Amelia Benjamin
Session: Poster Display session 2
Resources:
Abstract
1780 - Number of deliveries as a prognostic factor in different breast cancer subtypes
Presenter: Anniina Jääskeläinen
Session: Poster Display session 2
Resources:
Abstract
4650 - Effects of supervised and adapted exercise program in the quality of life and strength of breast cancer survivors: MAMA MOVE Gaia trial
Presenter: Ana Joaquim
Session: Poster Display session 2
Resources:
Abstract
4962 - Study On the Socioeconomic and Clinical Factors Affecting the Proportion of Breast Conserving Surgery in Chinese Women Breast Cancer
Presenter: Jin Zhang
Session: Poster Display session 2
Resources:
Abstract
5451 - Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?
Presenter: Marco Giavarra
Session: Poster Display session 2
Resources:
Abstract
888 - The value of genetic counselling in breast cancer genetic testing and clinical management
Presenter: Vicki Kiesel
Session: Poster Display session 2
Resources:
Abstract
4005 - Elderly patients in the Japanese Breast Cancer Registry
Presenter: Masataka Sawaki
Session: Poster Display session 2
Resources:
Abstract